Anavex Life Sciences Corp. Stock News

The CHMP agrees that Anavex's (AVXL) blarcamesine for Alzheimer's disease is eligible for submission for a Union Marketing Authorisation in the EU. Shares rise.

Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of

Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q4 2023 Earnings Call Transcript November 27, 2023 8:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President and CEO Sandra Boenis

Webcast and Conference Call To be Held Monday, November 27, 2023, 8:30 am ET Webcast and Conference Call To be Held Monday, November 27, 2023, 8:30 am ET

Anavex (AVXL) announces an encouraging regulatory update for its investigational candidate, blarcamesine, in the treatment of Alzheimer's disease. The stock rises 12%.

Anavex's Alzheimer's drug Blarcamesine demonstrates strong statistical significance in improving cognition among dementia patients as measured by one co-primary endpoint and one secondary endpoint. Fo

Anavex Life Sciences Corp. presented follow-on data from its Alzheimer's disease trial. This data uses a statistical methodology that is difficult to understand. It appears that the trial, despite the

NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeu

Webcast and Conference Call To be Held Tuesday, August 8, 2023, 8:30 am ET Webcast and Conference Call To be Held Tuesday, August 8, 2023, 8:30 am ET

Not much has happened at Anavex Life Sciences Corp. since my last coverage in March. There are a few pieces of news, which I cover here. The toplining of their pivotal trials will be an endgame I will

Anavex Life Sciences (NASDAQ:AVXL) Corp announced earlier this week that its Rett syndrome treatment showed a disease-modifying effect in a long-term clinical trial.  On news of the results, analysts

NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeu

Here is how Anavex Life Sciences (AVXL) and Clene Inc. (CLNN) have performed compared to their sector so far this year.

Blarcamesine, a sigma-1 receptor agonist, may be a more effective antioxidant than Aricept and galantamine in treating Alzheimer's disease. If granted accelerated approval by the FDA, Anavex's stock v

The average of price targets set by Wall Street analysts indicates a potential upside of 338.5% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionab